All In Biotech

Drug Trial Radar · NCT07170800

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE)

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 19, 2025

Primary completion

Feb 28, 2026

Study completion Sep 4, 2026

Sponsor

Lead sponsor
WestVac Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.

Conditions

  • Tuberculosis
  • Multidrug Resistant Pulmonary Tuberculosis
  • Rifampicin-resistant Tuberculosis

Interventions

  • JDB0131 100mgDrug

    Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.

  • JDB0131 200mgDrug

    Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 200 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.

  • Delamanid (D)Drug

    Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. Delamanid (D): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients with Sputum Culture Conversion (SCC)Time frame: During the 8-week treatment period and after treatment

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Huashan Hospital Fudan University

    Shanghai, China · Not yet recruiting

  • Wuhan Pulmonary Hospital

    Wuhan, Hubei, China · Recruiting

  • Changsha Central Hospital

    Changsha, Hunan, China · Recruiting

  • The Second Hospital of Nanjing

    Nanjing, Jiangsu, China · Recruiting

  • Shandong Public Health Clinical Center

    Jinan, Shandong, China · Recruiting

  • Public Health Clinical Center of Chengdu

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.